Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?

Background: Combination therapy with immune checkpoint inhibitors (ICIs) has been widely used for clinical treatment in recent years, which has a better survival benefit. However, not all patients can derive clinical benefit from combination immunotherapy. Therefore, it is necessary to explore the b...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yuqian, Jin, Huimin, Guo, Kaibo, Xiang, Yuying, Zhang, Yiting, Du, Wurong, Shen, Minhe, Ruan, Shanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949479/
https://www.ncbi.nlm.nih.gov/pubmed/33716732
http://dx.doi.org/10.3389/fphar.2021.572845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949479/
https://www.ncbi.nlm.nih.gov/pubmed/33716732
http://dx.doi.org/10.3389/fphar.2021.572845

Ejemplares similares